Research programme: targeted alpha-particle radiotherapeutics - Affibody/Algeta

Drug Profile

Research programme: targeted alpha-particle radiotherapeutics - Affibody/Algeta

Alternative Names: 227Th-Affibody® molecule radioimmunoconjugate; Radiotherapeutics - Affibody/Algeta; Thorium-227-Affibody® molecule radioimmunoconjugate

Latest Information Update: 11 Mar 2014

Price : $50

At a glance

  • Originator Affibody; Algeta
  • Class Proteins; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Mar 2014 Algeta has been acquired by Bayer
  • 01 Mar 2013 Algeta amends its licence for tumour-targeted molecules with Affibody
  • 05 May 2011 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top